EXHALE-3

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults with Severe Eosinophilic Asthma

Study Name:
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults with Severe Eosinophilic Asthma

Targeted Disease(s):
Asthma

Purpose of Study:

The purpose of this study, EXHALE-3, is to assess the efficacy and safety of Dexpramipexole, an oral eosinophil maturation inhibitor, in patients ≥12 years of age with inadequately controlled severe eosinophilic asthma (GINA Step 4 or 5) and a history of exacerbations. The primary endpoint of this study is the annualized rate of asthma exacerbations.

Study Dates:
March 27, 2023 - July 30, 2026

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Funding Source:
Areteia Therapeutics

Contact:

EXHALE Recruiting: 888-584-9281
[email protected]

ClinicalTrails.gov Identifier:
NCT05813288

Register for Trial
Asthma Basics Workshop - National
, | Apr 17, 2024
Asthma Basics Workshop - National
, | May 07, 2024